MCID: WTH001
MIFTS: 37

Withdrawal Disorder malady

Categories: Mental diseases

Aliases & Classifications for Withdrawal Disorder

Aliases & Descriptions for Withdrawal Disorder:

Name: Withdrawal Disorder 12 14
Withdrawal Syndrome 52 14
Substance Withdrawal Syndrome 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0060001

Summaries for Withdrawal Disorder

Disease Ontology : 12 A substance-related disorder that occurs upon the abrupt discontinuation/separation or a decrease in dosage of the intake of medications, recreational drugs, and alcohol.

MalaCards based summary : Withdrawal Disorder, also known as withdrawal syndrome, is related to barbiturate dependence and neonatal abstinence syndrome, and has symptoms including seizures, drug withdrawal symptoms and withdrawal symptoms. An important gene associated with Withdrawal Disorder is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Peptide ligand-binding receptors and G alpha (s) signalling events. The drugs Clonidine and Morphine have been mentioned in the context of this disorder. Related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Withdrawal Disorder

Diseases related to Withdrawal Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 42)
id Related Disease Score Top Affiliating Genes
1 barbiturate dependence 11.1
2 neonatal abstinence syndrome 10.7
3 hole retinal cyst 10.3 AR KLK3
4 colon signet ring adenocarcinoma 10.2 AR KLK3
5 glioblastoma mesenchymal subtype 10.2 AR KLK3
6 trachea adenoid cystic carcinoma 10.2 KLK3 POMC
7 bagassosis 10.1 KLK3 POMC
8 acute contagious conjunctivitis 10.1 OPRM1 PDYN
9 endometrial mixed adenocarcinoma 10.1 KLK3 POMC
10 18p deletion syndrome 10.1 OPRM1 PDYN
11 allergic hypersensitivity disease 10.1 CNR1 FOS HTR7
12 vascular cancer 10.1 CNR1 FOS HTR7
13 extraosseous chondrosarcoma 10.1 PDYN POMC
14 capillary disease 10.1 AR KLK3 POMC
15 avoidant personality disorder 10.0 AR KLK3 POMC
16 transmitted_by 10.0 OPRM1 PDYN POMC
17 hypereosinophilic syndrome 10.0 CNR1 OPRM1 POMC
18 conjunctival pigmentation 10.0 CRH HTR7
19 mixed lacrimal gland cancer 9.9 FOS HTR7
20 kidney rhabdoid cancer 9.9 PDYN POMC
21 intermittent squint 9.9 CRH POMC
22 breast secretory carcinoma 9.9 CRH POMC
23 suppurative periapical periodontitis 9.9 FOS OPRM1 PDYN POMC
24 nonparalytic poliomyelitis 9.9 CRH POMC
25 dacryoadenitis 9.9 CRH POMC
26 hypogonadism cardiomyopathy 9.9 CRH POMC
27 early-onset parkinson disease 9.8 CRH POMC
28 capillary lymphangioma 9.8 AR CRH POMC
29 calcinosis 9.8 CRH KLK3 POMC
30 siberian tick typhus 9.8 CNR1 FOS HTR7 PDYN TSPO
31 fechtner syndrome 9.8 CRH POMC TSPO
32 hereditary multiple exostoses 9.8 CNR1 CRH POMC
33 femur bifid with monodactylous ectrodactyly 9.8 CRH POMC
34 benign epilepsy with centrotemporal spikes 9.8 CNR1 CRH POMC
35 keratosis 9.8 CRH HTR7 POMC
36 simultanagnosia 9.7 CNR1 HTR7 OPRM1 PDYN POMC
37 autism spectrum disorder 9.7 CNR1 HTR7 OPRM1 PDYN POMC
38 preeclampsia/eclampsia 5 9.7 CNR1 HTR7 OPRM1 PDYN POMC
39 cervical carcinosarcoma 9.6 CNR1 FOS HTR7 OPRM1 PDYN POMC
40 hypoglycemia 9.6 CNR1 CRH OPRM1 PDYN POMC
41 personality disorder 9.3 CNR1 CRH FOS HTR7 OPRM1 PDYN
42 autoimmune disease of endocrine system 8.4 AR CNR1 CRH FOS HTR7 JAG1

Graphical network of the top 20 diseases related to Withdrawal Disorder:



Diseases related to Withdrawal Disorder

Symptoms & Phenotypes for Withdrawal Disorder

UMLS symptoms related to Withdrawal Disorder:


seizures, drug withdrawal symptoms, withdrawal symptoms, opiate withdrawal symptoms

MGI Mouse Phenotypes related to Withdrawal Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.16 AR CNR1 CRH FOS HTR7 JAG1
2 homeostasis/metabolism MP:0005376 10.06 AR CNR1 CRH FOS HTR7 JAG1
3 cellular MP:0005384 10.03 AR CNR1 CRH FOS JAG1 OPRM1
4 growth/size/body region MP:0005378 10.02 TSPO AR CNR1 CRH FOS JAG1
5 adipose tissue MP:0005375 9.95 AR CNR1 CRH OPRM1 PDYN POMC
6 endocrine/exocrine gland MP:0005379 9.95 AR CRH FOS JAG1 OPRM1 POMC
7 integument MP:0010771 9.91 AR CNR1 CRH FOS HTR7 JAG1
8 nervous system MP:0003631 9.81 CNR1 CRH FOS HTR7 JAG1 OPRM1
9 no phenotypic analysis MP:0003012 9.43 PDYN POMC CNR1 CRH JAG1 OPRM1
10 normal MP:0002873 9.17 AR CNR1 CRH FOS JAG1 OPRM1

Drugs & Therapeutics for Withdrawal Disorder

Drugs for Withdrawal Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1409)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1 4205-90-7 2803
2
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
3
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 159351-69-6 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 128794-94-5 5281078
6
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 24280-93-1 446541
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 53123-88-9 5284616 6436030 46835353
9
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 104987-11-3 445643 439492
10
Basiliximab Approved, Investigational Phase 4,Phase 2 152923-56-3, 179045-86-4
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
13
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2 185243-69-0
14
Bupropion Approved Phase 4,Phase 2,Phase 3,Phase 1 34841-39-9, 34911-55-2 444
15
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
16
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
17
Fluoxetine Approved, Vet_approved Phase 4,Phase 3 54910-89-3 3386
18
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
19
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
20
Milnacipran Approved Phase 4,Phase 3,Phase 2 92623-85-3 65833
21
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
22
Etoricoxib Approved, Investigational Phase 4,Phase 3 202409-33-4 123619
23
Acamprosate Approved, Investigational Phase 4,Phase 2,Phase 3 77337-76-9 71158
24
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
25
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
26
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
27
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
28
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 50-78-2 2244
29
Sodium oxybate Approved Phase 4 502-85-2 5360545
30
Clozapine Approved Phase 4,Phase 3 5786-21-0 2818
31
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559
32
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
33
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
34
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1 2216-51-5 16666
35
Levobupivacaine Approved Phase 4 27262-47-1 92253
36
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 52485-79-7 40400 644073
37
Heroin Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 561-27-3 5462328
38
Gliclazide Approved Phase 4 21187-98-4 3475
39
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 437-38-7 3345
40
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59467-70-8 4192
41
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 137-58-6 3676
42
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 9005-49-6 772 46507594
43
Bisoprolol Approved Phase 4,Phase 1,Phase 2 66722-44-9 2405
44
Calcium carbonate Approved Phase 4,Phase 2,Phase 1 471-34-1
45
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
46
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
47 Moxonidine Approved Phase 4 75438-57-2 4810
48
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
49
Budesonide Approved Phase 4,Phase 2,Phase 3 51333-22-3 63006 5281004
50
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 465-65-6 5284596

Interventional clinical trials:

(show top 50) (show all 4234)
id Name Status NCT ID Phase
1 NAS Treatment - Opiate Versus Non-Opiate Unknown status NCT01734551 Phase 4
2 Efficacy of Certican® in Combination With Myfortic® in Renal Unknown status NCT01399242 Phase 4
3 Steroid Withdrawal Immunosuppression After Renal Transplantation Unknown status NCT01550445 Phase 4
4 Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4
5 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4
6 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4
7 Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit Unknown status NCT02025855 Phase 4
8 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4
9 Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain Unknown status NCT01264237 Phase 4
10 Acamprosate vs. Placebo in Bipolar Alcoholics Unknown status NCT00466661 Phase 4
11 Remission Induction in Very Early Rheumatoid Arthritis Unknown status NCT00523692 Phase 4
12 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4
13 Physiological Response to Heliox21 and Air O2 Unknown status NCT01498432 Phase 4
14 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome Unknown status NCT01823770 Phase 4
15 WHAT (Women, Hot-flashes, Activity, Trial) - Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women Unknown status NCT01282320 Phase 4
16 GRK4 Polymorphisms Blood Pressure Response to Candesartan Unknown status NCT01629225 Phase 4
17 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4
18 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4
19 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4
20 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis Unknown status NCT01042158 Phase 4
21 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4
22 A Dose Finding Study for Pain Relief of a Broken Hip Unknown status NCT00926666 Phase 4
23 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4
24 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
25 Variation in Sulphonylurea Response in Type 2 Diabetes Unknown status NCT00738088 Phase 4
26 The Psychological Effects of Different Sedation Protocol on Mechanically Ventilated Critically Ill Adults. Unknown status NCT02123589 Phase 4
27 Prophylactic Lidocaine Spray for Pain Alleviation in Women Undergoing Osmotic Dilator Insertion for Second Trimester Dilatation and Evacuation Unknown status NCT02097017 Phase 4
28 Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU Unknown status NCT01962116 Phase 4
29 BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study) Unknown status NCT02398929 Phase 4
30 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4
31 Alleviating the Metabolic Side Effects of Antipsychotic Medications Unknown status NCT01567124 Phase 4
32 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Unknown status NCT01846962 Phase 4
33 Nasal Naloxone for Narcotic Overdose Unknown status NCT01912573 Phase 4
34 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Unknown status NCT01059396 Phase 4
35 Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure Unknown status NCT00716573 Phase 4
36 Amantadine for Treatment of Symptoms of the Post-Traumatic Confusional State Unknown status NCT00693121 Phase 4
37 Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Completed NCT02090504 Phase 4
38 Treatment of Alcohol Withdrawal in Hospital Patients Completed NCT00249366 Phase 4
39 Electronic Cigarettes in Daily Dependent Smokers Completed NCT02108626 Phase 4
40 Nicotine Replacement Therapy in the Intensive Care Unit Completed NCT01362959 Phase 4
41 Lofexidine for Inpatient Opiate Detox in Singapore Completed NCT01675648 Phase 4
42 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4
43 Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal State in the ICU Completed NCT02496650 Phase 4
44 Drug Therapy for Alcohol Detoxification Completed NCT00000441 Phase 4
45 Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription Completed NCT00244465 Phase 4
46 Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal Completed NCT01573052 Phase 4
47 Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients Completed NCT01501929 Phase 4
48 Nicotine Patch for Marijuana Withdrawal Completed NCT01400243 Phase 4
49 Buprenorphine in the Emergency Department Completed NCT03174067 Phase 4
50 Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers Completed NCT01048944 Phase 4

Search NIH Clinical Center for Withdrawal Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Withdrawal Disorder

Anatomical Context for Withdrawal Disorder

Publications for Withdrawal Disorder

Variations for Withdrawal Disorder

Expression for Withdrawal Disorder

Search GEO for disease gene expression data for Withdrawal Disorder.

Pathways for Withdrawal Disorder

GO Terms for Withdrawal Disorder

Biological processes related to Withdrawal Disorder according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.74 CNR1 FOS OPRM1
2 aging GO:0007568 9.72 CNR1 FOS TSPO
3 response to ethanol GO:0045471 9.63 CNR1 CRH OPRM1
4 negative regulation of blood pressure GO:0045776 9.56 CNR1 CRH
5 response to morphine GO:0043278 9.54 CNR1 OPRM1
6 response to immobilization stress GO:0035902 9.52 CRH FOS
7 response to pain GO:0048265 9.51 CRH TSPO
8 adrenal gland development GO:0030325 9.49 CRH TSPO
9 chemical synaptic transmission GO:0007268 9.46 CRH HTR7 OPRM1 PDYN
10 response to corticosterone GO:0051412 9.43 CRH FOS
11 neuropeptide signaling pathway GO:0007218 9.43 OPRM1 PDYN POMC
12 regulation of N-methyl-D-aspartate selective glutamate receptor activity GO:2000310 9.4 CRH OPRM1
13 sensory perception GO:0007600 9.37 OPRM1 PDYN
14 regulation of synaptic transmission, GABAergic GO:0032228 9.32 CNR1 NISCH
15 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.13 CNR1 HTR7 OPRM1
16 response to cocaine GO:0042220 8.8 CNR1 CRH OPRM1
17 signal transduction GO:0007165 10.02 AR CNR1 CRH HTR7 OPRM1 POMC

Molecular functions related to Withdrawal Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 CRH PDYN
2 androgen binding GO:0005497 8.62 AR TSPO

Sources for Withdrawal Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....